文献速递乳腺CT

双能CT定量参数评估乳腺癌新辅助化疗疗效的价值

Value of Dual-Energy Computed Tomography Quantitative Parameters in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.
PubMed 文献 · Acad Radiol · 2026-03-04

回顾性分析43例经组织学确诊乳腺癌患者新辅助化疗前后的增强双能CT扫描数据,按术后Miller-Payne分级分为有效组(4-5级,18例)与无效组(1-3级,25例)。化疗后有效组动脉期ΔNIC%和ΔλHU%以及静脉期ΔNIC%、ΔλHU%和ΔED%均显著大于无效组。双能CT定量参数变化与乳腺癌新辅助化疗反应相关,提示其可能支持影像学疗效评估。

要点

  • 化疗后静脉期ΔNIC%、ΔλHU%和ΔED%在有效组显著大于无效组,可能有助于评估疗效。
  • 化疗前各定量参数在有效组与无效组间无统计学显著差异。
  • 动脉期ΔNIC%和ΔλHU%在化疗后有效组显著大于无效组。

核心结论

  • 双能CT定量参数变化,尤其是静脉期ΔNIC%、ΔλHU%和ΔED%,与乳腺癌新辅助化疗反应相关,提示双能CT指标可能支持影像学疗效评估。

研究设计与样本

  • 回顾性分析43例经组织学确诊乳腺癌患者新辅助化疗前后的增强双能CT扫描数据,按术后Miller-Payne分级分为有效组(4-5级,n=18)和无效组(1-3级,n=25)。

诊断标准与关键数值

  • 以术后Miller-Payne分级为参考标准:4-5级为有效组(n=18),1-3级为无效组(n=25)。
  • 化疗后有效组动脉期ΔNIC%和ΔλHU%显著大于无效组(均P<0.05)。
  • 化疗后有效组静脉期ΔNIC%、ΔλHU%和ΔED%显著大于无效组(均P<0.05)。
  • 化疗前NIC、λHU和ED在有效组与无效组间均无统计学显著差异(P>0.05)。

临床应用与阅片要点

  • 作者认为双能CT定量参数变化可能支持乳腺癌新辅助化疗疗效的影像学评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To investigate the value of dual-energy computed tomography (DECT) quantitative parameters and their percentage changes for evaluating the therapeutic response to neoadjuvant chemotherapy (NAC) in breast cancer.

MATERIALS AND METHODS: Clinical data from 43 patients with histologically confirmed breast cancer who underwent contrast-enhanced DECT scans before and after NAC were retrospectively analyzed. Based on the postoperative Miller-Payne (MP) grading system, patients were classified into an effective group (MP grades 4-5, n = 18) and an ineffective group (MP grades 1-3, n = 25). Quantitative parameters-including normalized iodine concentration (NIC), spectral slope (λHU), and electron density (ED)-were measured before and after NAC. The percentage changes (ΔNIC%, ΔλHU%, and ΔED%) were calculated and compared between the two groups.

RESULTS: Before NAC, no statistically significant differences were observed in any of the quantitative parameters (NIC, λHU, and ED) between the effective and ineffective groups (P > 0.05). After NAC, the effective group showed significantly greater ΔNIC% and ΔλHU% in the arterial phase, as well as significantly greater ΔNIC%, ΔλHU%, and ΔED% in the venous phase than did the ineffective group (all P < 0.05).

CONCLUSION: Changes in DECT-derived quantitative parameters, especially venous-phase ΔNIC%, ΔλHU%, and ΔED%, were associated with response to neoadjuvant chemotherapy in breast cancer, indicating the potential of DECT-based metrics to support imaging evaluation of treatment response.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Xiang R, Peng X, Lu X, et al. Value of Dual-Energy Computed Tomography Quantitative Parameters in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Acad Radiol. 2026. PMID: 41781263. doi:10.1016/j.acra.2026.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。